永安药业(002365.SZ)发布前三季度业绩，归母净利润2549.63万元，同比下降58.78%

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) reported a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating income of 577 million yuan, representing a year-on-year decrease of 6.72% [1] - The net profit attributable to shareholders of the listed company was 25.5 million yuan, down 58.78% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 5.18 million yuan, reflecting a significant decline of 86.17% year-on-year [1]